我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
11
9 进行中
药物批准
12
批准总数
监管机构
3
监管机构数
成立时间
1994
进行中（未招募）
8
72.7%
尚未招募
1
9.1%
招募中
2
18.2%
FDA
Food and Drug Administration
EMA
European Medicines Agency
6
CIMA_AEMPS
Spanish Agency for Medicines and Medical Devices
5
• The World Health Organization (WHO) has prequalified the MVA-BN vaccine, marking the first mpox vaccine to receive this designation, enhancing access in high-need communities. • The MVA-BN vaccine, given as a two-dose injection four weeks apart for adults over 18, shows approximately 82% effectiveness with the full regimen. • The Department of Health (DOH) Region 6 has issued a warning against unauthorized mpox vaccines lacking FDA approval, citing potential safety and efficacy risks. • WHO is also progressing with prequalification and emergency use listing procedures for two other mpox vaccines: LC-16 and ACAM2000.
